391 related articles for article (PubMed ID: 34548333)
1. Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in
Zundell JA; Fukumoto T; Lin J; Fatkhudinov N; Nacarelli T; Kossenkov AV; Liu Q; Cassel J; Hu CA; Wu S; Zhang R
Cancer Res; 2021 Oct; 81(20):5325-5335. PubMed ID: 34548333
[TBL] [Abstract][Full Text] [Related]
2. Targeting the IRE1α/XBP1s pathway suppresses CARM1-expressing ovarian cancer.
Lin J; Liu H; Fukumoto T; Zundell J; Yan Q; Tang CA; Wu S; Zhou W; Guo D; Karakashev S; Hu CA; Sarma K; Kossenkov AV; Zhang R
Nat Commun; 2021 Sep; 12(1):5321. PubMed ID: 34493732
[TBL] [Abstract][Full Text] [Related]
3. ARID1A-mutated ovarian cancers depend on HDAC6 activity.
Bitler BG; Wu S; Park PH; Hai Y; Aird KM; Wang Y; Zhai Y; Kossenkov AV; Vara-Ailor A; Rauscher FJ; Zou W; Speicher DW; Huntsman DG; Conejo-Garcia JR; Cho KR; Christianson DW; Zhang R
Nat Cell Biol; 2017 Aug; 19(8):962-973. PubMed ID: 28737768
[TBL] [Abstract][Full Text] [Related]
4. Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer.
Fukumoto T; Park PH; Wu S; Fatkhutdinov N; Karakashev S; Nacarelli T; Kossenkov AV; Speicher DW; Jean S; Zhang L; Wang TL; Shih IM; Conejo-Garcia JR; Bitler BG; Zhang R
Cell Rep; 2018 Mar; 22(13):3393-3400. PubMed ID: 29590609
[TBL] [Abstract][Full Text] [Related]
5. Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.
Mimura N; Fulciniti M; Gorgun G; Tai YT; Cirstea D; Santo L; Hu Y; Fabre C; Minami J; Ohguchi H; Kiziltepe T; Ikeda H; Kawano Y; French M; Blumenthal M; Tam V; Kertesz NL; Malyankar UM; Hokenson M; Pham T; Zeng Q; Patterson JB; Richardson PG; Munshi NC; Anderson KC
Blood; 2012 Jun; 119(24):5772-81. PubMed ID: 22538852
[TBL] [Abstract][Full Text] [Related]
6. Loss of p53 enhances the function of the endoplasmic reticulum through activation of the IRE1α/XBP1 pathway.
Namba T; Chu K; Kodama R; Byun S; Yoon KW; Hiraki M; Mandinova A; Lee SW
Oncotarget; 2015 Aug; 6(24):19990-20001. PubMed ID: 26254280
[TBL] [Abstract][Full Text] [Related]
7. IRE1α Disruption in Triple-Negative Breast Cancer Cooperates with Antiangiogenic Therapy by Reversing ER Stress Adaptation and Remodeling the Tumor Microenvironment.
Harnoss JM; Le Thomas A; Reichelt M; Guttman O; Wu TD; Marsters SA; Shemorry A; Lawrence DA; Kan D; Segal E; Merchant M; Totpal K; Crocker LM; Mesh K; Dohse M; Solon M; Modrusan Z; Rudolph J; Koeppen H; Walter P; Ashkenazi A
Cancer Res; 2020 Jun; 80(11):2368-2379. PubMed ID: 32265225
[TBL] [Abstract][Full Text] [Related]
8. Loss of HDAC-Mediated Repression and Gain of NF-κB Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer.
Kim M; Lu F; Zhang Y
Cell Rep; 2016 Sep; 17(1):275-288. PubMed ID: 27681437
[TBL] [Abstract][Full Text] [Related]
9. Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma.
Wu S; Fukumoto T; Lin J; Nacarelli T; Wang Y; Ong D; Liu H; Fatkhutdinov N; Zundell JA; Karakashev S; Zhou W; Schwartz LE; Tang HY; Drapkin R; Liu Q; Huntsman DG; Kossenkov AV; Speicher DW; Schug ZT; Van Dang C; Zhang R
Nat Cancer; 2021 Feb; 2(2):189-200. PubMed ID: 34085048
[TBL] [Abstract][Full Text] [Related]
10. Targeting Mitochondrial Metabolism in Clear Cell Carcinoma of the Ovaries.
Zhang X; Shetty M; Clemente V; Linder S; Bazzaro M
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33947138
[TBL] [Abstract][Full Text] [Related]
11.
Kawahara N; Yamada Y; Kobayashi H
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070839
[TBL] [Abstract][Full Text] [Related]
12. Resveratrol triggers the pro-apoptotic endoplasmic reticulum stress response and represses pro-survival XBP1 signaling in human multiple myeloma cells.
Wang FM; Galson DL; Roodman GD; Ouyang H
Exp Hematol; 2011 Oct; 39(10):999-1006. PubMed ID: 21723843
[TBL] [Abstract][Full Text] [Related]
13. IRE1α-XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity.
Song M; Sandoval TA; Chae CS; Chopra S; Tan C; Rutkowski MR; Raundhal M; Chaurio RA; Payne KK; Konrad C; Bettigole SE; Shin HR; Crowley MJP; Cerliani JP; Kossenkov AV; Motorykin I; Zhang S; Manfredi G; Zamarin D; Holcomb K; Rodriguez PC; Rabinovich GA; Conejo-Garcia JR; Glimcher LH; Cubillos-Ruiz JR
Nature; 2018 Oct; 562(7727):423-428. PubMed ID: 30305738
[TBL] [Abstract][Full Text] [Related]
14. Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis.
Zhou W; Liu H; Yuan Z; Zundell J; Towers M; Lin J; Lombardi S; Nie H; Murphy B; Yang T; Wang C; Liao L; Goldman AR; Kannan T; Kossenkov AV; Drapkin R; Montaner LJ; Claiborne DT; Zhang N; Wu S; Zhang R
Cancer Cell; 2023 Apr; 41(4):740-756.e10. PubMed ID: 36963401
[TBL] [Abstract][Full Text] [Related]
15. ER stress and distinct outputs of the IRE1α RNase control proliferation and senescence in response to oncogenic Ras.
Blazanin N; Son J; Craig-Lucas AB; John CL; Breech KJ; Podolsky MA; Glick AB
Proc Natl Acad Sci U S A; 2017 Sep; 114(37):9900-9905. PubMed ID: 28847931
[TBL] [Abstract][Full Text] [Related]
16. A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1/XBP1.
Ming J; Ruan S; Wang M; Ye D; Fan N; Meng Q; Tian B; Huang T
Oncotarget; 2015 Dec; 6(38):40692-703. PubMed ID: 26517687
[TBL] [Abstract][Full Text] [Related]
17. The IRE1α-XBP1 pathway positively regulates parathyroid hormone (PTH)/PTH-related peptide receptor expression and is involved in pth-induced osteoclastogenesis.
Tohmonda T; Yoda M; Mizuochi H; Morioka H; Matsumoto M; Urano F; Toyama Y; Horiuchi K
J Biol Chem; 2013 Jan; 288(3):1691-5. PubMed ID: 23235147
[TBL] [Abstract][Full Text] [Related]
18. ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma.
Sato E; Nakayama K; Razia S; Nakamura K; Ishikawa M; Minamoto T; Ishibashi T; Yamashita H; Iida K; Kyo S
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890703
[TBL] [Abstract][Full Text] [Related]
19. Calreticulin promotes EMT in pancreatic cancer via mediating Ca
Sheng W; Wang G; Tang J; Shi X; Cao R; Sun J; Lin YH; Jia C; Chen C; Zhou J; Dong M
J Exp Clin Cancer Res; 2020 Oct; 39(1):209. PubMed ID: 33028359
[TBL] [Abstract][Full Text] [Related]
20. HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer.
Fukumoto T; Fatkhutdinov N; Zundell JA; Tcyganov EN; Nacarelli T; Karakashev S; Wu S; Liu Q; Gabrilovich DI; Zhang R
Cancer Res; 2019 Nov; 79(21):5482-5489. PubMed ID: 31311810
[No Abstract] [Full Text] [Related]
[Next] [New Search]
